专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09173896B2 RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions 有权
标题翻译：连接蛋白43的RNAi介导的抑制用于治疗IOP相关病症
公开(公告)号：US09173896B2
公开(公告)日：2015-11-03
申请号：US12371007
申请日：2009-02-13
申请人： Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
发明人： Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
IPC分类号： A61K31/713 , C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
摘要翻译：提供RNA干扰抑制连接蛋白43（Cx43）在眼内压相关条件下，包括眼高压和青光眼如正常眼压青光眼和开角型青光眼。

2. 发明授权

US09206428B2 RNAi-mediated inhibition of histamine receptor H1-related conditions 有权
标题翻译： RNAi介导的组胺受体H1相关病症的抑制
公开(公告)号：US09206428B2
公开(公告)日：2015-12-08
申请号：US14087344
申请日：2013-11-22
申请人： Arrowhead Research Corporation
发明人： John M. Yanni , Jon E. Chatterton , Daniel A. Gamache , Steven T. Miller
IPC分类号： C12N15/11 , C12N15/113
CPC分类号： C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/141
摘要： RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
摘要翻译：提供RNA干扰用于抑制组胺受体H1mRNA表达，特别是用于治疗患有HRH1相关病症或具有发生HRH1相关病症的风险的患者，例如过敏性结膜炎，眼部炎症，皮炎，鼻炎，哮喘或过敏。

3. 发明授权

US09150862B2 siRNA targeting VEGFA and methods for treatment in vivo 有权
标题翻译：靶向VEGFA的siRNA和体内治疗方法
公开(公告)号：US09150862B2
公开(公告)日：2015-10-06
申请号：US14010749
申请日：2013-08-27
申请人： Anja Smith , Angela Reynolds , Jon E. Chatterton , Xinyu Zhang
发明人： Anja Smith , Angela Reynolds , Jon E. Chatterton , Xinyu Zhang
IPC分类号： C07H21/04 , C12N15/113 , A61K31/713
CPC分类号： C12N15/1136 , A61K31/713 , C12N2310/14
摘要： Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulates the growth of new blood vessels, and overexpression of VEGFA can lead to undesirable physiological conditions. Through the identification of new siRNA and modifications that improve the silencing ability of these siRNA in vivo, therapeutic compositions and methods have been invented to address the problems associated with this overexpression.
摘要翻译：血管内皮生长因子A（VEGFA）是刺激新血管生长的细胞产生的化学信号，VEGFA的过度表达可导致不良生理条件。通过鉴定提高这些siRNA在体内的沉默能力的新siRNA和修饰，已经发明了治疗组合物和方法来解决与这种过度表达相关的问题。

4. 发明授权

US09133462B2 dsRNA for treating viral infection 有权
标题翻译：用于治疗病毒感染的dsRNA
公开(公告)号：US09133462B2
公开(公告)日：2015-09-15
申请号：US14069642
申请日：2013-11-01
申请人： Arrowhead Research Corporation
发明人： Mark Aron Labow , Larry Alexander Gaither , Jason Borawski
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译：本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽（PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。可以使用多种这样的dsRNA来提供治疗益处。本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。

5. 发明授权

US07700371B2 Method for determining an analyte 失效
标题翻译：测定分析物的方法
公开(公告)号：US07700371B2
公开(公告)日：2010-04-20
申请号：US10479249
申请日：2002-05-31
申请人： Kerstin Blank , Katrin Spinnler , Thao Mai , Filipp Oesterhelt , Ilka Gilbert , Boris Steipe , Hermann Gaub , Christian Albrecht , Gunnar Brink
发明人： Kerstin Blank , Katrin Spinnler , Thao Mai , Filipp Oesterhelt , Ilka Gilbert , Boris Steipe , Hermann Gaub , Christian Albrecht , Gunnar Brink
IPC分类号： G01N33/543
CPC分类号： G01N33/54366 , C12Q1/6837 , G01N33/543 , C12Q2565/515
摘要： The present invention relates to a method for determining an analyte in a sample. According to the method of the present invention, a probe is transferred from a stamp member onto an analyte that is bound to a support member. The present invention is particularly suitable for microarrays.
摘要翻译：本发明涉及一种用于测定样品中分析物的方法。根据本发明的方法，将探针从压印构件转移到与支撑构件结合的分析物上。本发明特别适用于微阵列。

6. 发明授权

US09371529B2 RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions 有权
标题翻译： RNAi介导的脾脏酪氨酸激酶相关炎症状态的抑制
公开(公告)号：US09371529B2
公开(公告)日：2016-06-21
申请号：US14270174
申请日：2014-05-05
申请人： Arrowhead Research Corporation
发明人： John M. Yanni , Jon E. Chatterton , Daniel A. Gamache , Steven T. Miller
IPC分类号： C12N15/113 , C07H21/02
CPC分类号： C12N15/1137 , A61K31/7105 , A61K31/713 , C07H21/02 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2320/30
摘要： RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
摘要翻译：提供RNA干扰用于抑制脾脏酪氨酸激酶（Syk）mRNA表达，特别是用于治疗患有Syk相关炎性病症的患者或具有发展Syk相关炎性病症如过敏性结膜炎，眼部炎症，皮炎，鼻炎，哮喘，过敏或肥大细胞疾病。

7. 发明授权

US09347062B2 Interfering RNA delivery system and uses thereof 有权
标题翻译：干扰RNA递送系统及其用途
公开(公告)号：US09347062B2
公开(公告)日：2016-05-24
申请号：US14156227
申请日：2014-01-15
申请人： Arrowhead Research Corporation
发明人： Ying Yu , Jon E. Chatterton
IPC分类号： A61K38/16 , C07K14/00 , C12N15/11 , C12N15/113 , A61K47/48 , A61K48/00 , C12N15/87
CPC分类号： C12N15/113 , A61K31/7088 , A61K47/645 , A61K48/0025 , A61K48/0033 , C12N15/111 , C12N15/1137 , C12N15/87 , C12N2310/14 , C12N2310/3513 , C12N2320/32 , C12Y502/01008
摘要： The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.
摘要翻译：本发明提供了包含细胞穿透肽，10个组氨酸和干扰RNA分子的递送系统。该系统可用于在体内或体外将干扰RNA分子递送至细胞中。还提供了用于输送系统的治疗用途。

8. 发明申请

US20150376621A1 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE 审中-公开
公开(公告)号：US20150376621A1
公开(公告)日：2015-12-31
申请号：US14711845
申请日：2015-05-14
申请人： ARROWHEAD RESEARCH CORPORATION
发明人： Jang HAN , Michael HOUGHTON
IPC分类号： C12N15/113 , A61K45/06
CPC分类号： C12N15/1131 , A61K31/713 , A61K45/06 , C12N15/111 , C12N2310/14 , C12N2310/322 , C12N2310/3515 , C12N2310/3533 , C12N2320/31
摘要： The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2′-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2′-Fluorine. The invention provides that the 2′-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3′ end of the molecule.

9. 发明授权

US09139834B2 RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis 有权
标题翻译： RNAi相关抑制TNFα信号通路治疗眼血管生成
公开(公告)号：US09139834B2
公开(公告)日：2015-09-22
申请号：US14270197
申请日：2014-05-05
申请人： Arrowhead Research Corporation
发明人： Jon E. Chatterton , Abbot F. Clark , David P. Bingaman , Martin B. Wax , Adrian M. Timmers
IPC分类号： C07H21/04 , C12N15/113
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
摘要翻译：通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症如眼血管生成，视网膜缺血和糖尿病性视网膜病变的风险的患者。

10. 发明授权

US09080175B2 Organic compositions to treat Beta-ENaC-related diseases 有权
标题翻译：治疗β-ENAC相关疾病的有机组合物
公开(公告)号：US09080175B2
公开(公告)日：2015-07-14
申请号：US14042924
申请日：2013-10-01
申请人： Arrowhead Research Corporation
发明人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
IPC分类号： C07H21/02 , C07H21/04 , A61K48/00 , C12N15/85 , C12N15/113 , A61K31/713
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
摘要翻译：本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂的RNAi试剂到β-ENaC。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式